Hepatitis Forums
Advanced Liver Disease Main Forums => Advanced Liver Disease => Topic started by: Hep Editors on May 08, 2020, 11:13:33 am
-
On March 10, the Food and Drug Administration (FDA) approved a combination of the checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) for people with advanced hepatocellular carcinoma (HCC), the most common type of liver cancer.
The accelerated approval was based on results from the Phase I/II CheckMate 040 trial, which showed a response rate of 33% among HCC patients previously treated with Nexavar (sorafenib).
Over years or decades, chronic hepatitis B or C, heavy alcohol use, fatty liver disease and other causes can lead to development of cirrhosis and hepatocellular carcinoma. Liver cancer is often detected late and is difficult to treat, as it does not respond well to traditional chemotherapy. The tyrosine kinase inhibitor Nexavar is a standard first-line treatment for advanced liver cancer, but it doesn’t work for many patients and most experience disease progression.
For more...
https://www.hepmag.com/article/fda-approves-immunotherapy-combination-liver-cancer